Marc Dechamps

Director/Board Member at OSE IMMUNOTHERAPEUTICS

Health Technology

Profile

Marc Dechamps is Chief Executive Officer at Bioxodes SA since 2022.
Mr. Dechamps is Independent Director at OSE Immunotherapeutics SA since 2024.
Formerly, Mr. Dechamps was Co-Managing Director at Catalent Gosselies PS SA. Mr. Dechamps was Director & Head-Business Development at eTheRNA immunotherapies NV.

Marc Dechamps active positions

Companies	Position	Start
OSE IMMUNOTHERAPEUTICS	Director/Board Member	18/06/2024
Bioxodes SA Bioxodes SA BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapeutics targeting thrombo-inflammation	Chief Executive Officer	30/09/2022

All active positions of Marc Dechamps

Former positions of Marc Dechamps

Companies	Position	End
Delphi Genetics SA Delphi Genetics SA BiotechnologyHealth Technology Develops DNA applications for bio-productions	Chief Executive Officer	30/06/2017
eTheRNA immunotherapies NV eTheRNA immunotherapies NV BiotechnologyHealth Technology Develops novel immunotherapies to overcome cancers and infectious diseases	Director/Board Member	-

See the detail of Marc Dechamps's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Marc Dechamps's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
Delphi Genetics SA Delphi Genetics SA BiotechnologyHealth Technology Develops DNA applications for bio-productions	Health Technology
Bioxodes SA Bioxodes SA BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapeutics targeting thrombo-inflammation	Health Technology
OSE Immunotherapeutics SA OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers	Health Technology
eTheRNA immunotherapies NV eTheRNA immunotherapies NV BiotechnologyHealth Technology Develops novel immunotherapies to overcome cancers and infectious diseases	Health Technology